Pharmaceutical New Product Planning Excellence: Structure and Roles

STUDY OVERVIEW

With so much riding on a new product launch, pharmaceutical organizations are under pressure to deliver effective products in shorter time frames. Leading companies use the New Product Planning (NPP) function to efficiently and effectively navigate the complicated drug development process to the point of a hand-off to product commercialization teams.

This research identifies the structure and roles of NPP groups, detailing the strengths and weaknesses of various NPP organizational structures and how the operational characteristics of the NPP function evolves as a company matures. In addition, the research examines the differences between global and regional NPP roles.

Best Practices, LLC undertook this benchmarking study to provide new product development leaders at pharmaceutical companies with insights into the structures and roles that leading NPP groups are using to strengthen the development process of their organization.

KEY TOPICS

• The State of New Product Planning
• New Product Planning Structure
• Roles, Responsibilities, Interaction & Influence

• Department that NPP Group reports to
• Level of person overseeing the NPP group and who they report to (in global, US-based global, regional, US-based regional NPP groups)
• How is your NPP function organized
• How effective is the structure of your NPP group
• How can the structure of your NPP group be improved
• Role of your NPP group in shaping portfolio decisions

• Global & Regional Teams Reporting Structure Vary: The scope of NPP responsibility for global and regional teams vary and accordingly, their reporting structure is also different. At 45% of global teams, VPs lead NPP teams and majority report to C-Suites. At U.S. based global groups, similar reporting structure is seen. Directors lead regional NPP groups at 40% of regional teams and report to VPs/ Senior VPs / Executive VPs at 50% of companies. At U.S. based regional NPP groups, Directors or VPs are responsible for NPP and report to CMOs.

METHODOLOGY

For this research project, Best Practices, LLC engaged 19 new product development leaders from 15 pharmaceutical, biotech, and life sciences companies.

Industries Profiled:
Biopharmaceutical; Pharmaceutical; Medical Device; Biotech; Health Care; Clinical Research; Laboratories; Manufacturing; Consumer Products; Diagnostic


Companies Profiled:
Alkermes; Zydus Cadila; GlaxoSmithKline ; Astellas; Roche; Novartis; Sanofi; Pfizer; Takeda Pharmaceuticals; Cytokinetics; Allergan; Medicago; Bayer; Galderma; Wockhardt

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.